Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effects of Empagliflozin Treatment on Cardiac Biomarkers in Adults With Metabolically Healthy Obesity: Results From a Randomized, Placebo-Controlled Clinical Trial

Mayo Clinic Proceedings(2021)10.1016/j.mayocp.2021.06.012Source: DataRank Database

Effects of Empagliflozin Treatment on Cardiac Biomarkers in Adults With Metabolically Healthy Obesity: Results From a Randomized, Placebo-Controlled Clinical Trial is a research paper published in Mayo Clinic Proceedings (2021). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.00)OA: greenTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Anubha Agarwal ORCID,Colby Ayers ORCID,Eunsook S. Jin ORCID,Ian J. Neeland ORCID,Sadiya S. Khan ORCID

Live enrichment

PubMed:34353477 PMC:PMC8446809 OpenAlex:https://openalex.org/W3188287751

American Heart Association Inc

Grant: 19TPA34890060

National Institutes of Health

Grant: UL1TR001105

National Institutes of Health

Grant: K23DK106520

National Institutes of Health

Grant: R01DK099289

National Institutes of Health

Grant: 5P30DK0929

National Institutes of Health

Grant: P30AG059988

National Institutes of Health

Grant: 1P30AG059988-01A1

The Claude D. Pepper Older Americans Independence Center (OAIC) at Northwestern University

National Institutes of Health

Grant: 4UL1TR001105-04

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)

National Institutes of Health

Grant: 5R01DK099289-04

13C asymmetry in blood glucose as a marker for oxidative stress in liver

National Institutes of Health

Grant: 5K23DK106520-05

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Merck

Novo Nordisk

FWCI

0.00

Citation Percentile

0.1%

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8446809

publisherhttps://api.elsevier.com/content/article/PII:S0025619621004870?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0025619621004870?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.mayocp.2021.06.012

Fields of Study

Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes03 medical and health sciences0302 clinical medicineAdultBenzhydryl CompoundsBiomarkersFemaleGlucosidesHumansMaleMiddle AgedMyocardial IschemiaObesity, Metabolically BenignRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsTroponin

MeSH Terms

Obesity, Metabolically BenignSodium-Glucose Transporter 2 InhibitorsAdultBenzhydryl CompoundsFemaleGlucosidesHumansMaleMiddle AgedTroponinBiomarkersRandomized Controlled Trials as TopicMyocardial Ischemia

Keywords

MedicineEmpagliflozinInternal medicineHeart failureDiabetes mellitusType 2 diabetesPopulationRandomized controlled trialPlaceboOverweightBody mass indexCardiologyEndocrinologyPathologyAdultMaleObesity, Metabolically BenignMyocardial IschemiaMiddle AgedTroponinGlucosidesHumansFemaleBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsBiomarkersRandomized Controlled Trials as Topic

Sustainable Development Goals

SDG 0: Good health and well-being